Paroxysmal nocturnal hemoglobinuria in pediatric patients-Reference-Cited by-同舟云学术

Paroxysmal nocturnal hemoglobinuria in pediatric patients

Published:2011-12-06 Issue:3 Volume:59 Page:525-529
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr. Blood Cancer

Author:

Curran Kevin J.,Kernan Nancy A.,Prockop Susan E.,Scaradavou Andromachi,Small Trudy N.,Kobos Rachel,Castro-Malaspina Hugo,Araten David,DiMichele Donna,O'Reilly Richard J.,Boulad Farid

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pbc.23410/fullpdf

Reference13 articles.

1. Paroxysmal nocturnal hemoglobinuria with onset in childhood and adolescence;Ware;N Engl J Med,1991

2. Natural history of paroxysmal nocturnal hemoglobinuria;Hillmen;N Engl J Med,1995

3. Paroxysmal nocturnal haemoglobinuria: Long-term follow-up and prognostic factors. French Society of Haematology;Socie;Lancet,1996

4. The pathophysiology of disease in patients with paroxysmal nocturnal hemoglobinuria;Bessler;Hematol Am Soc Hematol Educ Program,2008

5. Childhood paroxysmal nocturnal haemoglobinuria (PNH), a report of 11 cases in the Netherlands;van den Heuvel-Eibrink;Br J Haematol,2005

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics, pharmacodynamics, efficacy, and safety of ravulizumab in pediatric paroxysmal nocturnal hemoglobinuria;Blood Advances;2024-05-31

2. Transformation of aplastic anemia with paroxysmal nocturnal hemoglobinuria clone to childhood B‐cell precursor acute lymphoblastic leukemia;Pediatric Blood & Cancer;2024-04-11

3. Identification of Paroxysmal Nocturnal Hemoglobinuria-Type Bone Marrow Mast Cells;Cureus;2023-09-08

4. Characteristics of paroxysmal nocturnal hemoglobinuria patients in Brazil: A retrospective administrative claims database analysis of PNH patients in Brazilian public healthcare system;PLOS ONE;2023-07-26

5. Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome;Expert Review of Clinical Pharmacology;2023-05-04